Resistance to activated protein C (APCR), in the majority of cases due to the arginine506 (Arg506) to glutamine (Gln) mutation in the factor V gene, has emerged as the most important hereditary cause of venous thrombo-embolism. To determine to what extent this relatively common gene mutation influences the fibrinolytic system we investigated a population of APC resistant children (n = 65) in comparison with a control group␣of sex- and age-matched healthy children (n = 100). Compared to the controls, plasma levels of tissue-type plasminogen activator (t-PA), urokinase-type plasminogen activator (u-PA) and plasminogen activator inhibitor (PAI) 1 antigen, D-Dimer and enhanced thrombin generation were significantly (P < 0.0001) increased in children with the common factor V mutation. No difference was found between symptomatic and non-symptomatic children. Whether high concentrations of t-PA, u-PA and PA1 antigen can predict future vascular occlusion in children with APCR requires a more extensive multicentre study.
Conclusion Our data indicate that hypercoagulability in children with the Arg506 to Gln mutation in the factor V gene is mainly attributed to the genetic aetiology of the disease.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Received: 25 May 1996 / Accepted: 3 September 1996
About this article
Cite this article
Nowak-Göttl, U., Vielhaber, H., Grohmann, J. et al. Arginine506 to glutamin mutation in the factor V gene in infancy and childhood: evidence of fibrinolytic impairment. Eur J Pediatr 156, 195–198 (1997). https://doi.org/10.1007/s004310050581
- Key words Arg506 to Gln
- PAI 1